GlassScriptPhysician profile
Toney Graham
NPI 1841490869
$3,198.17
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $726 · 2021: $1,015 · 2022: $880 · 2023: $17.70 · 2024: $84.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.08 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $298.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $245.52 | 2020-2022 | |
| Amarin Pharma, INC. | $223.77 | 2019-2022 | |
| Amgen INC. | $219.06 | 2019-2021 | |
| Forte Bio-Pharma LLC | $216.13 | 2020-2022 | |
| Novo Nordisk INC | $190.33 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $156.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.51 | 2019-2022 | |
| Astellas Pharma US INC | $154.37 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.11 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $81.76 | 2020-2022 | |
| Pfizer INC. | $79.64 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $72.52 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $64.76 | 2022 | |
| Allergan, INC. | $59.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.99 | 2021-2024 | Xifaxan |
| Mylan Specialty L.P. | $45.38 | 2021-2022 | |
| Eisai INC. | $38.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.98 | 2021 | |
| Verity Pharmaceuticals INC. | $24.33 | 2024 | Tlando |
| Supernus Pharmaceuticals, INC. | $22.85 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.76 | 2022 | |
| Glaxosmithkline, LLC. | $12.42 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.29 | 2020 | |
| Merck Sharp & Dohme LLC | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toney Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.